Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
Terms of Use
Privacy Policy
Home Delivery
Submission Forms
Place an Ad
Local Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
9.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
9.350
Bid (Size)
8.790 (50)
Ask (Size)
9.540 (1)
Prev. Close
9.350
Today's Range
9.350 - 9.350
52wk Range
7.705 - 21.59
Shares Outstanding
68,762,960
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Why Shares of Editas Medicine Jumped This Week
January 26, 2023
It's been a seesaw month for the clinical-stage gene-editing biotech.
Via
The Motley Fool
Performance
YTD
+10.78%
+10.78%
1 Month
+10.78%
+10.78%
3 Month
-25.50%
-25.50%
6 Month
-40.97%
-40.97%
1 Year
-50.89%
-50.89%
More News
Read More
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
January 19, 2023
Via
Benzinga
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 19, 2023
From
Editas Medicine, Inc.
Via
Globe NewsWire
Analyst Expectations for Editas Medicine's Future
January 10, 2023
Via
Benzinga
Why Editas Medicine Stock Is Sliding Today
January 09, 2023
Via
The Motley Fool
Analyst Ratings for Editas Medicine
December 06, 2022
Via
Benzinga
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
Via
InvestorPlace
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 09, 2023
From
Editas Medicine, Inc.
Via
Globe NewsWire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Editas Medicine, Inc.
Via
Globe NewsWire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
Via
Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
December 05, 2022
Via
The Motley Fool
Why Editas Medicine's Shares Are Falling Thursday
November 17, 2022
Via
The Motley Fool
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
Via
The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
December 06, 2022
Via
Benzinga
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
December 06, 2022
From
Editas Medicine, Inc.
Via
Globe NewsWire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
December 01, 2022
From
Editas Medicine, Inc.
Via
Globe NewsWire
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
Via
The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
November 18, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Via
Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
Via
Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
November 18, 2022
Via
Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
November 18, 2022
Via
Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.